From dough on Twitter. COWEN Names with the best potential to report Q1 results in excess of consensus include $ALXN $CELG $EXEL $ICPT $IRWD $KERX $PCRX $VRTX
AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in Q3 2017 = 2000% POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
Trend has seriously changed. Superior drug and aggressive sales team. Sold my IRWD position and put it all on SGYP. I think Trulance will be the market leader within the next 36-48 months. GLTA
Overall I think we will see upside for IRWD in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? Do you guys find it difficult to know when to buy or sell something? I prefer to get my stocks from awesome-STOCKS.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks
I have a feeling IRWD will see a pullback now. What yall think? google awesomesto-cks - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
Good article on Ironwood in this weekends WSJ addition.
The ineptitude of the analysts was on full display yesterday during the question period after theCC. (Of course, it's axiomatic that if you have an important question, you never ask it during the CC. The Wedbush analyst (they of the $13 price target, which they recently raised from $10!!) was fumbling around asking whether they could see any signs of the oncoming Trulance launch. (Which would be like asking Walmart if they were concerned about the fact that someone was proposing to open a 7-11 near one of their stores.) The Ironwood execs studiously avoided mentioning Trulance and only noted that their focus was on mining the OTC market for more customers. Ironwood and Allergan together spent $250 million on sales and marketing alone in the US last year and are planning to up that to $280 million or so next year. The total number of scripts and patients keeps rising and every one of those is a bankable asset. Linzess has taken over 60% of the prescription CIC-C and IBS-C market and they have yet to put a dent in the sales of Amitiza. The analysts, though, persist in acting as if this is a zero-sum game. If Ironwood and Allergan were to fire the entire sales staff and eliminate the $100mm+ they are spending on advertising or promotion at this point, Linzess sales would keep on growing. The only difference would be an extra $250mm in profit.
Found a great no fee daytrading newsletter, vist T0pMarketGaIners.c0m and sign up...so glad I did
Synergy Pharmaceuticals Secures Approval for Linzess Competitor. It is about time to sell IRWD and buy SGYP at discount price.